Nav: Home

Cell Press selected to publish Molecular Therapy family of journals

October 28, 2016

Molecular Therapy, the official journal of The American Society of Gene and Cell Therapy (ASGCT), has a new home at Cell Press, a leading publisher of biomedical and chemical research and reviews. This exciting new publishing partnership, to begin in January 2017, will see Cell Press produce and distribute ASGCT's four journals, which include its flagship title along with open-access options Molecular Therapy -- Methods & Clinical Development, Molecular Therapy -- Nucleic Acids, and Molecular Therapy -- Oncolytics.

"We are delighted for this premier collection of journals in the exciting areas of genetic and cellular therapeutics to join the Cell Press family as a society partnership reflecting our shared interest in the translation of basic science into therapeutic advance," says CEO Dr. Emilie Marcus.

ASGCT (@ASGCTherapy), established in 1996, is a non-profit organization based in Milwaukee, Wisconsin that represents the largest community of basic researchers and clinicians devoted to the discovery of gene and cell therapies in the United States and worldwide. The Society launched Molecular Therapy in 2000, which has since become the most cited journal in gene therapy, and has expanded its offerings to the scientific community with new journal launches and special issues.

"ASGCT is excited to bring the Molecular Therapy family of journals to Cell Press," says President Dr. Cindy Dunbar. "This new relationship between the ASGCT and Cell Press should improve the dissemination of research breakthroughs in gene and cell therapies, thus enhancing our mission of using these therapies to alleviate human disease."

"The expertise of Cell Press and its reputation of excellent, world-leading quality couples well with Molecular Therapy's position as the leading international source for original research in gene and cell therapies," says Molecular Therapy Editor-in-Chief Dr. Seppo Yla-Herttuala. "These collective efforts will serve as the vehicle driving new science as it transforms the practice of medicine to the benefit of patients and society."

With the addition of ASGCT, Cell Press now publishes a total of 38 journals, including the flagship Cell, Neuron, Current Biology, and most recently Chem. Other selected society partners include: The American Society of Human Genetics (AJHG); the Biophysical Society (Biophysical Journal); the International Society for Stem Cell Research (Stem Cell Reports), and the Institute of Plant Physiology and Ecology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, and Chinese Society of Plant Biology (Molecular Plant).
About the Molecular Therapy Collection:

Molecular Therapy (@MolTherapy) is a monthly journal for international research on the development of molecular and cellular therapeutics to correct genetic and acquired diseases, including but not limited to research on gene transfer and editing, vector development and design, stem cell manipulation, vaccine development, pre-clinical target validation, safety/efficacy studies, and clinical trials. Editor-in-Chief: Seppo Ylä-Herttuala, University of Eastern Finland.

Molecular Therapy -- Methods & Clinical Development is a monthly, open-access journal publishing new methods and significant improvements to established research techniques in basic, translational, and clinical cell and gene therapy. Editor-in-Chief: Roland W. Herzog, University of Florida.

Molecular Therapy -- Nucleic Acids publishes open-access research each month targeted to the advances in nucleic acid-based therapeutics to treat and/or correct genetic and acquired disease. Editor-in-Chief: John Rossi, Beckman Research Institute of the City of Hope.

Molecular Therapy -- Oncolytics is a monthly, open-access journal focusing on the development and clinical testing of viral, cellular, and other biological therapies targeting cancer. Editor-in-Chief: Yuman Fong, Beckman Research Institute of the City of Hope.

For table of content alerts, please sign up at

Learn more about ASGCT at

Cell Press (@CellPressNews), an imprint of Elsevier, is a leading publisher of scientific research and reviews. We drive science forward and promote cross-pollination of ideas with our passion for excellence and commitment to innovation. Our aim is to engage the scientific community by communicating important, exciting discoveries made today that will impact the future of research. Visit To receive Cell Press media alerts, contact

Cell Press

Related Gene Therapy Articles:

Non-viral gene therapy to speed up cancer research
A new treatment method promises to speed up gene therapy research and could bring new, patient friendly cancer treatments to market faster.
Gene therapy promotes nerve regeneration
Researchers from the Netherlands Institute for Neuroscience and the Leiden University Medical Center have shown that treatment using gene therapy leads to a faster recovery after nerve damage.
Gene therapy for blood disorders
Delivering gene-regulating material to cells that live deep in our bone marrow and direct the formation of blood cells.
Realizing the potential of gene therapy for neurological disorders
Promising findings from preclinical animal studies show the potential of gene therapy for treating incurable neurological disorders.
Gene therapy vectors carrying the telomerase gene do not increase the risk of cancer
Researchers from the Spanish National Cancer Research Centre (CNIO) have shown in a new study that the gene therapy with telomerase that they have developed, and which has proven to be effective in mice against diseases caused by excessive telomere shortening and ageing, does not cause cancer or increase the risk of developing it, even in a cancer-prone setting.
More Gene Therapy News and Gene Therapy Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Rethinking Anger
Anger is universal and complex: it can be quiet, festering, justified, vengeful, and destructive. This hour, TED speakers explore the many sides of anger, why we need it, and who's allowed to feel it. Guests include psychologists Ryan Martin and Russell Kolts, writer Soraya Chemaly, former talk radio host Lisa Fritsch, and business professor Dan Moshavi.
Now Playing: Science for the People

#537 Science Journalism, Hold the Hype
Everyone's seen a piece of science getting over-exaggerated in the media. Most people would be quick to blame journalists and big media for getting in wrong. In many cases, you'd be right. But there's other sources of hype in science journalism. and one of them can be found in the humble, and little-known press release. We're talking with Chris Chambers about doing science about science journalism, and where the hype creeps in. Related links: The association between exaggeration in health related science news and academic press releases: retrospective observational study Claims of causality in health news: a randomised trial This...